Bank of New York Mellon’s Filana Therapeutics FLNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$24.1K Sell
20,284
-197
-1% -$281 ﹤0.01% 4261
2026
Q1
$34.6K Hold
20,481
﹤0.01% 4157
2025
Q4
$40.6K Buy
20,481
+9,818
+92% +$31.4K ﹤0.01% 4147
2025
Q3
$31K Hold
10,663
﹤0.01% 4148
2025
Q2
$19.3K Sell
10,663
-99,995
-90% -$178K ﹤0.01% 4114
2025
Q1
$166K Sell
110,658
-136
-0.1% -$343 ﹤0.01% 3926
2024
Q4
$261K Buy
110,794
+2,952
+3% +$51.8K ﹤0.01% 3853
2024
Q3
$3.17M Sell
107,842
-33,005
-23% -$760K ﹤0.01% 2540
2024
Q2
$1.74M Buy
140,847
+21,558
+18% +$454K ﹤0.01% 2875
2024
Q1
$2.42M Sell
119,289
-13,129
-10% -$303K ﹤0.01% 2667
2023
Q4
$2.98M Sell
132,418
-2,686
-2% -$56.7K ﹤0.01% 2630
2023
Q3
$2.25M Buy
135,104
+3,739
+3% +$74.1K ﹤0.01% 2753
2023
Q2
$3.22M Buy
131,365
+4,080
+3% +$98.3K ﹤0.01% 2578
2023
Q1
$3.07M Sell
127,285
-2,365
-2% -$65.5K ﹤0.01% 2560
2022
Q4
$3.83M Buy
129,650
+856
+0.7% +$30.8K ﹤0.01% 2492
2022
Q3
$5.39M Buy
128,794
+12,408
+11% +$335K ﹤0.01% 2256
2022
Q2
$3.27M Sell
116,386
-6,607
-5% -$167K ﹤0.01% 2548
2022
Q1
$4.57M Buy
122,993
+712
+0.6% +$30.2K ﹤0.01% 2475
2021
Q4
$5.34M Sell
122,281
-1,270
-1% -$66.6K ﹤0.01% 2437
2021
Q3
$7.67M Sell
123,551
-7,808
-6% -$652K ﹤0.01% 2263
2021
Q2
$11.2M Sell
131,359
-15,226
-10% -$816K ﹤0.01% 2072
2021
Q1
$6.59M Sell
146,585
-21,016
-13% -$827K ﹤0.01% 2316
2020
Q4
$1.14M Buy
167,601
+32,313
+24% +$288K ﹤0.01% 3184
2020
Q3
$1.56M Hold
135,288
﹤0.01% 2818
2020
Q2
$417K Buy
135,288
+57,583
+74% +$261K ﹤0.01% 3565
2020
Q1
$320K Buy
77,705
+55,600
+252% +$368K ﹤0.01% 3574
2019
Q4
$115K Hold
22,105
﹤0.01% 4006
2019
Q3
$26K Hold
22,105
﹤0.01% 4164
2019
Q2
$27K Hold
22,105
﹤0.01% 4174
2019
Q1
$29K Sell
22,105
-171
-0.8% -$196 ﹤0.01% 4134
2018
Q4
$19K Hold
22,276
﹤0.01% 4163
2018
Q3
$22K Sell
22,276
-17,349
-44% -$26.4K ﹤0.01% 4205
2018
Q2
$81K Sell
39,625
-1,248
-3% -$10.7K ﹤0.01% 4030
2018
Q1
$289K Buy
40,873
+207
+0.5% +$1.4K ﹤0.01% 3812
2017
Q4
$163K Sell
40,666
-1,145
-3% -$4.62K ﹤0.01% 3991
2017
Q3
$171K Sell
41,811
-98
-0.2% -$350 ﹤0.01% 3904
2017
Q2
$174K Buy
41,909
+17,224
+70% +$81.3K ﹤0.01% 3929
2017
Q1
$154K Buy
24,685
+2,410
+11% +$10.9K ﹤0.01% 3939
2016
Q4
$88K Sell
22,275
-364
-2% -$1.69K ﹤0.01% 4046
2016
Q3
$158K Sell
22,639
-1,042
-4% -$17.3K ﹤0.01% 3943
2016
Q2
$363K Hold
23,681
﹤0.01% 3664
2016
Q1
$370K Hold
23,681
﹤0.01% 3556
2015
Q4
$290K Sell
23,681
-56
-0.2% -$741 ﹤0.01% 3744
2015
Q3
$305K Buy
23,737
+56
+0.2% +$707 ﹤0.01% 3758
2015
Q2
$286K Sell
23,681
-14,973
-39% -$205K ﹤0.01% 3797
2015
Q1
$511K Buy
38,654
+50
+0.1% +$675 ﹤0.01% 3598
2014
Q4
$549K Sell
38,604
-391
-1% -$6.77K ﹤0.01% 3580
2014
Q3
$1.07M Sell
38,995
-25
-0.1% -$760 ﹤0.01% 3247
2014
Q2
$1.57M Buy
39,020
+30,215
+343% +$1.12M ﹤0.01% 3046
2014
Q1
$339K Buy
8,805
+1,015
+13% +$35.8K ﹤0.01% 3700
2013
Q4
$265K Sell
7,790
-9
-0.1% -$239 ﹤0.01% 3779
2013
Q3
$149K Sell
7,799
-1,420
-15% -$24.8K ﹤0.01% 3863
2013
Q2
$143K Buy
+9,219
New +$195K ﹤0.01% 3845

Other funds holding FLNA

Bank of New York Mellon's FLNA Position: Q2 2026 in Review

Bank of New York Mellon reduced its Filana Therapeutics (FLNA) stake by 0.96% in Q2 2026, selling an estimated $281 and leaving 20,284 shares worth $24.1K. The position accounts for ﹤0.01% of the portfolio, ranked #4261.

Bank of New York Mellon first reported a position in FLNA in Q2 2013 and has held it in 53 quarters since. The position peaked at $11.2M in Q2 2021. 45 funds tracked by Wall St. Rank hold FLNA as of Q2 2026.

  • Bank of New York Mellon held 20,284 shares of Filana Therapeutics worth $24.1K as of Q2 2026.
  • Bank of New York Mellon sold 197 Filana Therapeutics shares in Q2 2026, an estimated $281.
  • Filana Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #4261 holding.
  • Bank of New York Mellon first reported a position in Filana Therapeutics in Q2 2013 and has held it in 53 quarters since.
  • Bank of New York Mellon's Filana Therapeutics position peaked at $11.2M in Q2 2021.
  • 45 funds tracked by Wall St. Rank held Filana Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.